Satellite glial cells (SGCs) are unique cells whose most distinctive morphological feature is that they wrap around neuronal cell bodies, in most cases forming a complete envelope. SGCs are found exclusively in peripheral ganglia — sensory, parasympathetic and sympathetic ganglia (Fig. 1a,b). The latter two are part of the autonomic nervous system. The gap between SGCs and the neuronal surface is about 20 nm, which is similar to that of the synaptic cleft. This organization allows for close mutual neuron–SGC interactions1–3. The neuron and its attendant SGCs have been termed ‘neuron–glial units’ (Fig. 1c). In most cases, neurons are wrapped individually with several SGCs, but there is evidence that a small proportion (4–9% depending on the species) of dorsal root ganglia (DRG) neurons share a common glial envelope, forming a ‘cluster’ with one or two other neurons14 (Fig. 1d). In some cases, the neurons in a cluster are separated only by a thin layer of extracellular space, whereas in other cases they are separated by a thin glial sheet, which allows neuron–SGC–neuron chemical interaction5.

Much more is known about astrocytes than SGCs, so it is instructive to compare SGCs with these as well as with other types of glia (BOX 1). Two main hallmarks of astrocyte–neuron relations are that each astrocyte contacts numerous neurons, and that individual astrocytes form non-overlapping domains6. In contrast, SGCs around a given neuron are in close contact with each other, and are almost always separated from SGCs surrounding other neurons.

The close contact between SGCs and neurons is a major key to understanding their functions; for example, this contact enables them to control neuronal homeostasis, but very little is known on this topic. More is known with regard to changes that SGCs in sensory ganglia undergo following nerve damage and how they contribute to pain. Little is known about the functions of SGGs in sympathetic ganglia, but there is emerging information on their role in the control of synaptic transmission in these ganglia. Knowledge of SGCs in parasympathetic ganglia is even scarcer.

Satellite glial cells (SGCs). Glial cells that surround neurons in sensory, sympathetic and parasympathetic ganglia (they should not be confused with satellite cells, which are the progenitor cells in striated muscles).
cord participate in pain generation and maintenance, and may serve as more suitable targets for pain therapy. This view was supported by studies of pain models in animals, showing that spinal microglia and astrocytes are essential for hyperalgesia7,15,16.

Sensory ganglia contain the somata of neurons that innervate most body parts. The main sensory ganglia are the DRG, trigeminal ganglia (TG) and nodose ganglia (Fig. 1). There is evidence that abnormal electrical activity in sensory neurons is associated with pathological pain, such as allodynia17–20. For example, it has been shown that phantom limb pain in humans is driven primarily by abnormal intrinsic DRG activity21. The ideas described above concerning CNS glia and pain prompted research into the possible role of SGCs in sensory ganglia in pain. It was found that nerve damage or inflammation activates SGCs in sensory ganglia. This included upregulation of the astrocyte marker glial fibrillary acidic protein (GFAP) in SGCs, as well as the release of inflammatory cytokines and chemokines by SGCs22–24. These findings suggest that SGCs may play a role in the development and maintenance of chronic pain.

**Fig. 1 | Location and morphology of SGCs.**

**a** | Position of the dorsal root ganglia (DRG) in the sensory pathways leading from the skin to the brain. A paravertebral sympathetic ganglion (SG) is also indicated. These ganglia innervate most organs, including blood vessels.

**b** | Location of the trigeminal ganglion (asterisk) which innervates the face and teeth. The three divisions of the trigeminal ganglion are indicated as V1–V3.

**c** | Low-power electron micrograph showing the neuron–satellite glial cell (SGC) units in a DRG. Neurons are labelled N1–N6, SGCs are coloured blue. The widened area in the SGC surrounding N3 contains the cell's nucleus. ct, connective tissue space; v, blood vessels. Scale bar, 10 µm.

**d** | Schematic of three patterns of grouping of sensory neurons. Top: neurons are separated by a connective tissue space (indicated by arrow), and each has its own SGC sheath. Middle: a cluster of two neurons that share a common SGC sheath and are separated by a SGC process. Bottom: a cluster where the neurons share a common SGC sheath, but without an intervening SGC process.

**e** | Schematic of a sympathetic neuron covered with an SGC envelope. The SGCs (arrows) cover the synapses. SGC processes extend beyond the neuronal soma and ensheath an axon and a dendrite. Part c adapted with permission from REF.86, Elsevier. Part e adapted with permission from REF.127, Elsevier.
Dorsal root ganglia (DRG). Clusters of cells located near the spinal cord containing the cell bodies of peripheral neurons that innervate most body parts, including internal organs.

Sensory ganglia Clusters of neuron cell bodies that have a single axon that bifurcates to two branches, one branch runs to the periphery and can detect various stimuli, and the other projects into the central nervous system.

P2 purinergic receptors (P2Rs). Receptors for the neurotransmitter adenosine (P1) and ATP (P2). There are seven ionotropic receptors (P2X1–P2X7) and eight G protein-coupled receptors (P2Y1–P2Y14).

**Box 1 | What sorts of glia are SGCs?**

Satellite glial cells (SGCs) exhibit similarities and differences compared with CNS astrocytes and oligodendrocytes:
- **Morphology**: whereas astrocytes and oligodendrocytes are highly branched and polarized, SGCs are flattened (see the figure, parts a, b). There is no evidence for contacts between SGCs and blood vessels, analogous to the endfeet that astrocytes make with blood vessels, and unlike oligodendrocytes, SGCs do not myelinate (with the exception of those in spiral ganglia).
- **Microenvironment control**: astrocyte transporters and ion channels control glutamate and K+ levels at synapses. SGCs express K+ channels and glutamate transporters, and probably perform similar control and protective functions.
- **Electrical coupling**: both astrocytes and SGCs are interconnected by gap junctions. This coupling is stronger and more extensive in astrocytes than in SGCs, but in both cell types, coupling increases following damage.
- **Molecular markers**: SGCs share marker molecules with all types of CNS glia and represent an intermediate type between astrocytes and oligodendrocytes. Like astrocytes, SGCs express glutamine synthetase, S100, vimentin, glutamate aspartate transporter (GLAST), connexin 43 (Cx43) and Kir4.1 potassium channels. Consistent with this, SGCs can function as progenitor cells, giving rise to neurons; indeed, silencing Kir4.1 in the TG leads to pain-like behaviour. Similarly, gain or loss of Kir4.1 in astrocytes that contact the somata of CNS neurons can regulate neuronal activity.

**Characteristics of SGCs**

**Ion channels.** SGCs do not have voltage-dependent Na+ or Ca2+ channels, and therefore cannot conduct action potentials. The main K+ channel in SGCs is Kir4.1 (REF. 19). Injury suppresses Kir4.1 function in SGCs, which may contribute to pain. Reduced Kir4.1 permeability likely depolarizes SGCs, inducing them to release excitatory mediators such as ATP that can activate the neurons; indeed, silencing Kir4.1 in the TG leads to pain-like behaviour. Similarly, gain or loss of Kir4.1 in astrocytes that contact the somata of CNS neurons can regulate neuronal activity.

**Gap junctions in SGCs.** Glial cells in both the CNS and the periphery express gap junction channels, which provide a pathway for diffusion of ions and small molecules between cells. The most abundant connexins (Cx) in mouse DRG and TG are Cx43 and Cx32, followed by Cx30.2, Cx37, Cx26, Cx30, Cx45 and Cx36 (REF. 39). Under normal conditions, SGCs contain Cx43 (REF. 40). Cx43 is upregulated in the TG and DRG following nerve injury or inflammation. Cx26 expression...
The concept of glial activation derives from the field of immune cell activation. In the presence of danger signals, immune cells transform into an activated state, which is manifested by increased cytokine production, action as antigen-presenting cells and phagocytosis of invading cells. Glial cells, and in particular microglia, can function as immune cells, and it was proposed that activation of glial cells in the spinal cord is a key process in chronic pain. A hallmark of astrocyte activation is an increased glial fibrillary acidic protein (GFAP) expression, and it was found that peripheral injury also induced this effect in satellite glial cells (SGCs) in sensory ganglia. Moreover, SGCs in human trigeminal ganglia act as antigen-presenting cells and are able to phagocytose dead neurons during development in mouse dorsal root ganglia (DRGs). SGCs express macrophage markers, such as MHC type II, CD40 and CD54, but not others (CD14 and CD68), and thus appear to have a unique leukocyte phenotype. It was proposed that SGC activation includes elevated GFAP, increased coupling by gap junctions and elevated sensitivity to ATP. Increased production of pro-inflammatory cytokines in activated SGCs was also noted. Disruption of neuronal p75NTR expression induced higher levels of GFAP, p75NTR and connexin 43 (Cx43), and lower levels of Kir4.1 protein in SGCs. Thus, the definition of SGC activation extends beyond GFAP upregulation.

The increased coupling between SGCs following injury is of special interest, as this can contribute to the spread and enhancement of neuronal excitation. One way of assessing coupling is the dye coupling method. Under resting conditions (see the figure, part a), SGCs are dye-coupled to other SGCs around the same neuron. The SGC marked with an asterisk was injected with the fluorescent dye Lucifer yellow, which crosses gap junctions, and the dye spread to three other SGCs. In the DRG of a mouse treated with the chemotherapeutic drug oxaliplatin, which causes neuropathic pain, dye spread occurs also to SGCs around adjacent neurons (see the figure, part b). These results correlate with electron-microscopic studies that showed increased numbers of gap junctions between SGCs following injury or inflammation. Scale bar, 20 μm. After nerve injury (see the figure, part c), SGCs that are part of the glial sheaths of two distinct neurons (N1 and N2) form a bridge where they are connected by gap junctions. The boxed area in part c (in the outlined area) is also shown at higher enlargement (see the figure, part d), where a gap junction is indicated with an arrow. Asterisk indicates an unmyelinated axon.

going onto to in TG demonstrate electrical coupling through SGC–SGC, neuron–SGC and neuron–neuron gap junctions.

As SGC activity is accompanied with increased coupling, it was proposed that blocking gap junctions could have an analgesic action, and this was confirmed in numerous chronic pain models. Reduced Cx43 in rat TG using double-stranded RNA was analgesic in a model of neuropathic pain induced by infraorbital nerve injury, although a potential concern was that in naive rats this treatment itself induced pain-like behaviours. A recent study has shown that increased SGC coupling contributes also to acute pain induced by capsaicin application. Blocking gap junctions with carbeneoxolone (CBX) or blocking P2X7Rs (which are expressed exclusively by SGCs) reduced pain reactions in this model, supporting a role for SGCs in acute pain.

In summary, increased coupling between SGCs and also SGC–neuron and neuron–neuron coupling is a common feature in pain models, and appears to contribute to chronic pain. We propose that inhibiting gap

---

**Trigeminal ganglia**

(TG). Clusters of cells located at the base of the skull (but outside the brain) that contain the cell bodies of neurons that innervate the face, teeth and scalp.

**Nodose ganglia**

Clusters of neuron cell bodies that innervate many visceral organs, such as the intestine and heart.

**Allodynia**

Pain resulting from a nonnoxious stimulus to normal skin.
junctions might be an effective novel target for analgesic drugs.

**Pannexins in SGCs.** Pannexins (Panx) are homologues of gap junction proteins of multicellular invertebrates, the innexins. Although Panxl does not form gap junctions, it does form membrane channels that allow release of ATP\(^{27,28}\). Panx1 expression is upregulated in the DRG following sciatic nerve ligation\(^{39}\), in TG SGCs in a chronic orofacial pain model\(^{40}\) and in nodose ganglia SGCs in a systemic inflammation model\(^{41}\). In the orofacial pain study\(^{40}\), Panx1-deleted mice did not develop tactile hypersensitivity, suggesting a role for Panx1-mediated ATP release in nociception. This anaglossic effect was obtained in mice with glia-targeted but not with neuron-specific Panxl deletion\(^{41}\), indicating the dominant role of SGCs in ATP release.

**Receptors.** Knowledge regarding the pharmacology of SGCs is still limited, and much of the information on this topic relates to purinergic transmission. ATP is a messenger in neuron–glia interactions\(^{41}\) and in the pain pathways\(^{42-44}\). Cells release ATP by vesicular or channel-mediated mechanisms, such as P2X7R or Panx1 channels. Ecto-ATPases break down ATP to ADP and other purines. In the DRG, ecto-ATPases are found in Schwann cells and SGCs, but not in neurons\(^{45}\). This enables these glial cells to regulate the ATP level in the ganglia.

Using calcium imaging, SGCs in the TG were found to express functional P2YRs (ReFS 2). Further work showed that P2Rs in the TG consist of P2Y1, P2Y2, P2Y4, P2Y6, P2Y12 and P2Y13Rs (ReFS 2,5,68,80,81). In vitro incubation with the pro-inflammatory peptide bradykinin increased the SGC response to P2YR stimulation\(^{46}\), indicating P2YR sensitization. Release of ATP by sensory neurons can activate P2Rs in SGCs, providing one mechanism for neuron–SGC communication\(^{47-49}\) (FiG. 2a,b). In two orofacial pain models, the sensitivity of SGCs to ATP in the TG increased 100-fold\(^{41}\), apparently due to a switch of the P2R population from the metabotropic P2YR to the ionotropic P2XR. The exact P2XR subtype that was increased was not determined but the candidates are P2X2, P2X4 and P2X5Rs, but not P2X7Rs which were reported to be equally present in SGCs in ganglia from both controls and treated animals\(^{41}\). Increased responses to ATP were also observed in a mouse model of systemic inflammatory pain in SGCs of the DRG\(^{47}\) and nodose ganglia\(^{41}\). It thus appears that P2R upregulation is part of the SGC activation after injury. There is little information on the pharmacology of SGCs in non-rodent mammals, but P2X7R expression is reportedly upregulated in DRG SGCs of patients with neuropathic pain\(^{41}\). These changes, combined with the increased sensitivity of sensory neurons to ATP under pathological conditions\(^{47,21}\), indicate that increased intercellular communication via P2Rs is likely to contribute to neuronal hyperexcitability in pain states (FiG. 2a,b).

Sensory neurons contain several neuroactive peptides, among which calcitonin gene-related peptide (CGRP) is one of the best studied, as it appears to be a major factor in migraine. In the TG of humans, rats and monkeys, the neurons express CGRP and SGCs express components of the CGRP receptor complex\(^{22,23}\), which suggests that this peptide mediates neuron–SGC communication. Recently, antibodies against CGRP and its receptors have been approved for migraine therapy, and it was found that they enter sensory ganglia but not the CNS\(^{41}\). This raises the possibility that the therapeutic action of these antibodies may involve disruption of abnormal neuron–SGC interactions.

Further study of SGC pharmacology is crucial for understanding the function of SGCs because chemical signalling is the main mode of glia–neuron communication. Recent technical developments allow recording of the physiological activity of sensory neurons in intact mice\(^{44,47,76}\), and this method can be utilized to explore the pharmacology of SGCs in vivo.

**SGCs and intercellular communication.** Neurons in sensory ganglia receive no synapses and are separated from each other by SGCs and the connective tissue space (FiG. 1c). It would therefore appear that no interactions among neurons in these ganglia are present; however, Devor and Wall\(^{77}\) showed that electrical activity in DRG neurons evokes depolarization in adjacent neurons, and named this ‘cross depolarization’ (FiG. 2c,d). Later work indicated that the effect is due to the release of unidentified chemical mediators\(^{48,79}\). Currently, there is evidence that SGCs contribute to cross depolarization, and that they interact chemically among themselves and with neurons via P2Rs (ReFS 2,5,68,80,81) and by gap junctions\(^{47}\). A calcium imaging study on the DRG in intact mice found that electrical activity in one neuron can activate neighbouring ones (‘coupled activation’)\(^{44}\). This effect was greatly increased after nerve injury or peripheral inflammation, and was attributed to Cx43 upregulation in SGCs. Coupled activation was reduced by local or systemic application of the gap junction blocker CBX and also in Cx43 knockout mice. Pain hypersensitivity behaviour was reduced by CBX. These observations indicate that gap junctions in SGCs are a major contributor to coupled activation and pain. The underlying mechanism of coupled activation is not fully clarified, but it was suggested that neuron–SGC–SGC–neuron electrical coupling is involved\(^{44}\) (see FiG. 3a,b). This idea is consistent with the enhanced cell coupling observed in rodent pain models\(^{48}\), but the contribution of chemical interactions was not excluded.

Studies on short-term TG cultures have shown that SGCs can transmit Ca\(^{2+}\) waves, which enable SGCs (together with neurons) to propagate signals over long distances\(^{46,47}\) (FiG. 2a,b). These waves are mediated by gap junctions and chemical messengers (ATP and glutamate). After nerve injury, gap junctions are upregulated and the sensitivity of both neurons and SGCs to ATP increases. It is thus expected that neuron–neuron interactions will be increased after injury, as indeed was observed in mouse pain models\(^{44}\).

Nerve damage induces prominent changes in SGCs, and as the injury site can be a large distance from the ganglion, determining which neuronal signals induce these changes has been a puzzle. A likely explanation is that the high firing rate in injured neurons causes the release of chemical mediators that act on SGCs and
activate them. Such mediators may include cytokines, growth factors and nitric oxide. Active neurons release nitric oxide, which diffuses rapidly over the narrow gap between them and the SGCs. Nitric oxide mimics the observed changes in SGCs that occur after nerve insult, and thus appears to be a key element in SGC activation.

We have proposed a scheme to explain how increased gap junctional communication and sensitization to ATP can explain the role of SGCs in neuronal hyperexcitability in pain models, based on the ‘ignition theory’ formulated to account for trigeminal neuralgia. In this model, hyperexcitability of sensory neurons is evoked...
by nerve injury. Activation of one neuron then spreads to others, achieving synchronized and sustained activity within neuronal ensembles. In the original framework, the synchronized discharge was hypothesized to result from chemical cross-excitation. It is conceivable that the increased neuronal activity leads to ATP release through upregulated Panx1 channels and that responses are amplified as a consequence of P2R activation in SGCs, and additional opening of Panx1 channels. Release of other molecules, including nitric oxide, cytokines and growth factors, likely also contributes to SGC activation. A modified ignition model based on

Fig. 3 | Injury-induced changes in neuron–SGC bidirectional communications. a,b | Proposed mechanism of coupled activation between neurons. Synchronous activity of adjacent neurons could arise by the spread of depolarization from neuron 1 (N1) to its surrounding satellite glial cells (SGCs), then through gap junctions to SGCs of a nearby neuron and then through gap junctions from these SGCs to N2. Under control conditions, SGCs are coupled mostly to other SGCs around a given neuron (part a). After peripheral injury or inflammation to a neuron (coloured red), SGCs become more strongly coupled to other SGCs around the same neuron (and also to neurons) by newly formed gap junctions. This enables increased transfer of electrical current and small molecules among SGCs and between SGCs and neurons. Such a mechanism can account for coupled neuronal activation (part b). c,d | The chain of events connecting neuronal excitation and glial activation. Resting conditions are shown in part c. Following neuronal damage, the neuronal cell body fires a high rate of action potentials, which increases intracellular calcium that in turn activates nitric oxide synthase to produce nitric oxide. Nitric oxide diffuses from the neuron and reaches the surrounding SGCs, where it induces cyclic guanosine 5’-monophosphate (cGMP) synthesis. This second messenger can have various actions on SGCs, and may be a key factor in SGC activation. SGC activation includes the release of ATP and cytokines, gap junction formation and increased sensitivity to ATP (part d). NO, nitric oxide; P2R, P2 purinergic receptor; Panx1, pannexin 1; TNF, tumour necrosis factor; TRPV1, transient receptor potential vanilloid type 1 channel.
the ability of glial cells to sustain intercellular calcium waves would include the spread of signals among SGCs through Ca\(^{2+}\) wave propagation\(^{26,27}\) (Fig. 2a,b). Enhanced gap junction-mediated coupling among SGCs, combined with enhanced P2R transmission, would spread the activation to other sensory neurons, leading to sustained reverberating activity and recruitment of non-nociceptors into the pain response.

The ideas discussed above are summarized in Fig. 3c,d and Fig. 4, which emphasize abnormal bidirectional SGC–neuron interactions that lead to enhanced neuronal activity.

**SGCs in selected pain conditions**

Numerous models have been used to study pain in animals\(^{48}\). Most models are based on local injury to peripheral nerves, and include nerve section (axotomy) and tissue incision. Local inflammation models include chronic constriction injury or the application of substances such as carrageenan or complete Freund’s adjuvant to the paw, face\(^{49}\) and teeth\(^{50}\). Models of systemic pain include inflammation induced by lipopolysaccharide (LPS)\(^{27,51}\), neuropathy following systemic administration of anticancer drugs\(^{52}\) and type 1 diabetes mellitus induced by streptozotocin (STZ)\(^{53,54}\). A role for SGCs in chronic pain has been documented in models of both localized and systemic types of chronic pain (somatic, visceral and orofacial). Several studies have demonstrated that reversing injury-induced changes in SGCs reduced or abolished pain behaviour in rodent models. Below, we describe the possible contributions of SGCs to several pain syndromes that are commonly encountered in clinical practice.

**Systemic inflammation.** Systemic inflammation is a common human disease. The ensemble of symptoms associated with this disorder is called ‘sickness behaviour’, and includes depression and pain\(^{46}\). As for most other pain syndromes, many investigators have emphasized the role of central mechanisms in sickness behaviour, with increased cytokine levels being a major factor. However, recent work suggests that activity initiated by LPS injection and sustained within the sensory ganglia contributes to the generation and maintenance of pain in systemic inflammation\(^{55}\). Moreover, a single intraperitoneal LPS injection induced changes in the DRG, which were associated with mechanical hypersensitivity that lasted for at least a month\(^{56}\). Apparently, the direct effects of LPS are short-lived and depend on its binding to Toll-like receptor 4 (TLR4) in sensory neurons, but the downstream sequelae can last for weeks. LPS-induced changes in SGCs were similar to those observed in local inflammatory pain models, which include SGC activation and increased SGC–SGC, neuron–SGC and neuron–neuron dys coupling by gap junctions\(^{57,58}\). Increased numbers of gap junctions in SGCs were detected by electron microscopy at both 7 and 30 days post LPS administration\(^{59}\). Neuronal gap junctions were not detected either before or after LPS injection, which is consistent with the very weak coupling of neurons to each other and to SGCs\(^{60}\).

In addition, LPS administration increased the responses of SGCs to ATP and reduced the withdrawal threshold in response to mechanical stimulation of the paw or abdomen. Intraperitoneal injection of the gap junction blocker CBX or palmatoleic acid raised the pain threshold back to the control level, suggesting a role for gap junctions in pain. These (and other) gap junction blockers are not highly specific and may act by other mechanisms and locations (for example, those that cross the blood–brain barrier may act centrally). However, CBX does not cross the blood–brain barrier\(^{61}\) and is therefore likely to act largely in the periphery, and gap junction blockers did not affect the withdrawal threshold in control mice. These findings support the idea that increased gap junction expression in sensory ganglia contributes to chronic pain, and indicate that gap junction blockade in these ganglia has therapeutic potential for alleviating chronic pain.

**Chronic post-surgical pain (PSP).** PSP can be acute (resolving within several days after the operation) or chronic (lasting months and even years). Chronic PSP is observed in 10–50% of patients undergoing common operations, such as hip and knee operations and mastectomy\(^{62,63}\). Current therapy for chronic PSP is inadequate, and preventive treatments have been largely ineffective\(^{4}\).

It is thought that chronic PSP is caused by nerve injury — that is, it is neuropathic — but this topic is
Central sensitization
A state when the central nervous system becomes highly reactive, causing even mild stimuli to be sensed as painful.

Extracellular-signal regulated kinase (ERK). A member of the MAP kinase family that is involved in multiple cellular processes.

Controversial. For example, skin and muscle incision and retraction in rats without visible nerve injury induced chronic PSP that persisted for more than 3 weeks, suggesting that mechanisms other than nerve injury are involved in chronic PSP. It is assumed that chronic PSP is associated with central sensitization, but peripheral mechanisms are also important, as peripheral activity drives the central sensitization in PSP and in other pain states.

Little is known regarding peripheral mechanisms in chronic PSP. Activation of P2X7R on SGCs was found to elevate phosphorylated ERK (pERK1/2) in SGCs, which led to TNF release. TNF in turn acts on neurons, which increases neuronal excitability. These results indicate that SGCs are a key element in chronic PSP generation and may be a highly suitable therapeutic target for it. Sensory ganglia are not protected by a vascular barrier, and therefore SGCs, which surround the neurons, are ideal targets for pain therapy.

In a PSP model based on paw incision, pERK1/2 expression was found to be increased 2-fold in A-fibre neurons and SGCs in the DRG. This increase was observed as early as 2 min after the incision, and returned to baseline at 2 h. This effect is extremely fast, especially considering that SGCs are not influenced directly by the injury and must receive signals from the neurons. The local anaesthetic levobupivacaine inhibited pERK1/2 induction. CBX, which blocks both gap junctions and Panx1 channels, inhibited the early glial pERK1/2 increase and also inhibited pain hypersensitivity. This study indicates that early events induced in SGCs by nerve injury participate in the generation of hypersensitivity in PSP. It is thus likely that preventing these events will have therapeutic value in PSP treatment.

Diabetic neuropathic pain (DNP). Nerve damage (neuropathy) is a common complication in diabetes mellitus type 1 and 2; it affects about 50% of the patients and is difficult to treat. A frequent consequence of this neuropathy is DNP. Little is known about the mechanisms responsible for DNP, but it is clear that both central and peripheral mechanisms contribute.

The most widely used diabetes mellitus type 1 model is obtained by injecting rodents with the toxin STZ, which destroys pancreatic beta cells. The key element in diabetes mellitus models is a severe-fold increase in the blood glucose level, which induces numerous types of cellular damage.

Injury to the peripheral nervous system in diabetes mellitus is well recognized. Research has mostly focused on axons, but there is evidence that functional changes in sensory neurons can contribute to DNP. Ionic currents in sensory neurons are abnormal in diabetes mellitus, indicating that sensory ganglia are highly suitable targets for research and therapy of DNP. SGCs can release the cytokines TNF and IL-1β, particularly following insults, so neuronal excitation by SGC-derived cytokines may be one way in which SGCs contribute to DNP.

Altered enzymatic activity in SGCs might be relevant to cellular damage in diabetes mellitus. One such enzyme is aldose reductase, which catalyses the conversion of glucose into sorbitol. Increased sorbitol production in cells leads to its accumulation, causing osmotic swelling and cell damage. Aldose reductase activity is present in SGCs (but not in neurons) of rat DRG. Targeting aldose reductase in SGCs seems to have promising potential for treating DNP, and efforts are underway to develop aldose reductase inhibitors as therapy for diabetes mellitus complications.

There is evidence for SGC activation in the STZ model. The underlying mechanism for this activation appears to be related to the hyperglycaemia-induced upregulation of pyruvate dehydrogenase kinases (PDK2 and PDK4) in DRG cells (SGCs, neurons and infiltrating macrophages). These enzymes play key roles in glucose metabolism, and their enhanced activity causes lactic acidosis, which activates SGCs and macrophages. Reactive SGCs and macrophages release pro-inflammatory cytokines (TNF, IL-1β and IL-6), which increase neuronal excitability and thus lead to pain. It can be concluded from this work that PDKs play a pivotal role in inducing SGC activation and creating a pro-inflammatory microenvironment in diabetic DRG, the prerequisites for pain pathogenesis.

The pharmacology of SGCs in diabetes mellitus models has received only limited attention. It was found that in parallel with the activation of SGCs in the STZ model, the sensitivity of these cells to the P2X7R agonist BzATP was increased. However, BzATP is a potent agonist of other P2XRs, particularly P2X4R, and indeed there is evidence that P2X4R is upregulated in SGCs in the STZ model and that it is essential for the mechanical hypersensitivity observed in this model. This topic needs to be further explored, particularly from the perspective of the degree to which SGC–neuron interaction is compromised and whether Cx43 or Panx1 is involved in the heightened P2R sensitivity in SGCs.

Post-herpetic neuralgia. Alphaherpesviruses, varicella zoster virus (VZV), herpes simplex virus type 1 (HSV-1) and HSV-2 infect the peripheral nervous system. After the primary infection, these viruses can become latent within sensory ganglia for the lifetime of the host, but retain the ability to reactivate and cause disease episodes. Reactivation of VZV results in herpes zoster, which is characterized by painful skin eruptions (shingles) and often leads to post-herpetic neuralgia. Reactivation of HSV causes mucocutaneous lesions (for example, cold sores) and may also result in neuralgia. Post-herpetic neuralgia can be severe, persistent and refractory to treatment. The mechanisms underlying this condition are not known. VZV is difficult to study because it does not infect rodents, and instead HSV-1 is used in rodent studies.

The role of SGCs in herpetic infection and pain has been controversial. Major questions are whether SGCs are actually infected and whether they contain the virus during latency. Another open question is whether abnormal SGC–neuronal interactions are present in herpes-infected ganglia, which could potentially contribute to post-herpetic pain.

To overcome the lack of a rodent model for VZV, Zerboni et al. grafted fetal human DRG under the kidney capsule of severe combined immunodeficiency mice. The grafted ganglia were infected with VZV, and
examined histologically after various periods (up to 20 weeks). This innovative approach clearly showed that the virus was present in both DRG neurons and SGCs\(^{121}\), see Box 3.

Cutaneous HSV-1 infection in mice was reported to promote infiltration of leukocytes into the DRG, where they release cytokines that downregulate the expression of Kir4.1 channels in SGCs\(^{122}\). Although it was assumed that the inflammatory mediators were present in the skin, the authors did not evaluate whether release could be from DRG-resident cells (SGCs, for example). It should also be added that infection of DRG cells by the virus was not verified, and it could be argued that the changes in the DRG could be due to the skin lesion caused by the virus and subsequent release of cytokines. It is notable that there is no conclusive demonstration of GFAP upregulation in SGCs in herpes, although there is evidence from western blots for GFAP elevation in the DRG after infection with HSV-1 (REF \(^\text{123}\)).

Few studies have examined the functional consequences of HSV infection on cells within sensory ganglia. In one such study, freshly dissociated TG neurons and SGCs were infected with HSV-1 and studied after 48 h in vitro\(^{124}\), at which time both the neurons and SGCs were infected. Calcium imaging, dye injections and intracellular electrical recordings from the neurons revealed several notable changes in these cultures. First, intercellular Ca\(^{2+}\) waves, which involved both neurons and SGCs, were more extensive in the infected cultures than in controls, which is consistent with greater spread of neural activity\(^{125}\). These waves were largely mediated by ATP acting on P2Rs in neurons and SGCs. Neuronal, but not glial, sensitivity to ATP was increased by the viral infection. Second, dye coupling among cells (neuron–neuron, neuron–SGC and SGC–SGC) was greatly increased. This coupling was not mediated by gap junctions but by cell fusion, which is known to occur following infection with alphaherpesviruses\(^{123,124}\), see Box 3. Apparently, the ATP-mediated Ca\(^{2+}\) wave propagation is facilitated by the direct connection of the cytoplasm of cells. Third, electrical recordings from the neurons showed a widening of the action potentials in neurons from infected cultures compared with controls, consistent with greater influx of Ca\(^{2+}\). This would raise intracellular Ca\(^{2+}\) levels, leading to increased release of mediators, including ATP. Thus, the enhanced Ca\(^{2+}\) waves are explained by greater sensitivity of neurons to ATP, by cell fusion and by greater Ca\(^{2+}\) influx into the neurons. The increased Ca\(^{2+}\) waves and neuronal hyperexcitability may lead to increased neuronal firing, and thus to pain. These results help in understanding the peripheral mechanisms of pain in herpes, but need to be validated in animal models where HSV-1 infection is made in vivo. A limitation of the in vitro work is that it does not provide information on long-term events and reactivation.

**SGCs in other types of viral infections**

Infections by viruses other than herpesvirus may also involve SGCs. Of special interest is HIV-1, the virus that causes AIDS, in which peripheral neuropathy and pain are common. Infection with simian immunodeficiency virus is a useful model to study HIV. In macaques nodules, which are clusters of SGCs that occupy the space of degenerated neurons\(^{126}\). Friedreich ataxia is a genetic disease characterized by deficiency in frataxin, a mitochondrial protein. Patients with Friedreich ataxia suffer from impaired movement and cardiac functions. In the DRG of patients with Friedreich ataxia, SGCs are activated and form numerous gap junctions and abnormal multiple layers around the neurons\(^{127}\). Part a adapted from REF \(^\text{124}\), CC BY 4.0.
SGCs in sympathetic ganglia

Most of the available knowledge on SGCs in autonomic ganglia is on sympathetic ganglia, and therefore only these ganglia are discussed here. As in sensory ganglia, SGCs in sympathetic ganglia wrap around the neurons, but gaps in the envelope may occur. A major difference between SGCs in sympathetic and sensory ganglia is the presence of synapses in sympathetic ganglia, where SGCs form a layer over the synapses, enabling them to control synaptic transmission. This arrangement is similar to the ‘synaptic cradle’ proposed for astrocyte–neuron arrangement in the CNS. Acetylcholine (ACh) is the major neurotransmitter in sympathetic ganglia, and indeed it was found that SGCs in the mouse superior cervical ganglion (sympathetic) are sensitive to ACh, which is consistent with the idea that there is a match between chemical messengers in neurons and the receptors in adjacent glia. A later work showed that selective injury to sympathetic nerve terminals activated SGCs in superior cervical ganglia, but not in sensory ones. Conversely, LPS-induced inflammation, which activated SGCs in sensory ganglia, had no effect on SGCs in the superior cervical ganglia. This selective activation correlates with the presence of TLR4 in sensory neurons, and their absence in sympathetic ones. The results above are supported by a recent study, which showed that SGCs in sympathetic ganglia release factors that augment cholinergic synaptic transmission. SGCs also promote synapse formation and contribute to neuronal survival. Thus, SGCs play crucial roles in both development and maintenance of sympathetic function.

There is evidence that the sympathetic nervous system is involved in pain mechanisms, but this topic is controversial. Most notable is the possible role of sympathetic nerves in complex regional pain syndrome. Animal studies have shown that nerve damage augments interactions between sympathetic and sensory ganglia. For example, damage causes sympathetic fibres to sprout in the DRG, and in two models of DRG nerve injury there was an inflammatory response in sympathetic ganglia infected with simian immunodeficiency virus there was an upregulation of GFAP in DRG SGCs, but its contribution to the disease is not known. Another virus family is coronavirus that includes MERS-CoV, SARS-CoV and SARS-CoV-2 (which causes COVID-19), which are highly infective and can be fatal in humans. Information on the involvement of SGCs in coronavirus infections is minimal, but there are some clues from a study on another member of this family — swine haemagglutinating encephalomyelitis virus, which is highly lethal in pigs. An electron-microscopic study of haemagglutinating encephalomyelitis virus–infected rats found that the virus replicated in DRG neurons. Viral particles were secreted from neurons, and were taken up by SGCs and located in lysosome-like structures, indicating that SGCs can restrict the virus spread. This protective function is consistent with the ability of SGCs to phagocytose pathogens, as described in Box 1.

Future perspectives

We expect that the increasing interest in SGCs and the application of newly developed research tools will enable progress in novel areas of this field. Future directions in SGC research that we believe may be particularly fruitful are the following. First, injury to sensory neurons causes the attraction of macrophages into the ganglia, and they even penetrate into the space between SGCs and neurons. Macrophages release various pro-inflammatory substances, which can increase neuronal firing. Studying macrophage–SGC interactions seems a promising direction. It was found that SGCs and macrophages promote regeneration of DRG axons, and this topic needs to be probed in depth. Second, methods are now available to isolate SGCs, which allows the analysis of their transcriptomes under normal and pathological conditions. For example, single-cell RNA sequencing will enable a search for SGC subtypes and a comparison between SGCs from different types of ganglia, topics on which we currently know nothing. Third, most available information on SGCs has been obtained in rodents, which limits its applicability to clinical situations. Human sensory ganglia are becoming available for laboratory research, which opens exciting possibilities for validating in human material the concepts that have been developed in rodent studies. Using ganglia from patients will help in learning more about the role of SGCs in human disorders, such as migraine and post-herpetic pain. Extending the study on SGCs in viral diseases should receive high priority, as these cells may be a novel therapeutic target. Fourth, use of genetically encoded activity indicators in intact animals potentially allows the observation of interactions between neurons and SGCs in sensory ganglia and could provide novel information regarding such interactions in autonomic ganglia as well. These techniques are certain to provide insight into pathological activity patterns and to enable testing of pharmacological strategies to reverse the pathological changes. Finally, current knowledge of SGCs in autonomic ganglia is very limited, but in view of the recent work, which revealed novel and important roles of these cells in sympathetic ganglia, we expect that this area will attract growing attention.
Concluding remarks

We describe here possible roles of SGCs in four important pain syndromes. These syndromes have different clinical manifestations, and each may be mediated by different biochemical and physiological mechanisms. Still, the observations that SGCs in sensory ganglia are altered in a similar way in these models (as well as in other models that were not mentioned) suggest that changes in these cells are a general feature of chronic pain. The location of sensory ganglia outside the blood–brain barrier, and the arrangement of SGCs around the neurons, make SGCs an ideal therapeutic target for chronic pain. Similarly, auto-
nomic ganglia are more accessible to intravascular agents than is the brain parenchyma4, and SGC modulation of sympathetic output might be targeted for disturbances of heart rhythm, blood pressure and other disorders.

Published online 22 July 2020
